Reporte zur Charge 616796

Symptomtext

COVID 19 Treatment; COVID 19 Treatment; Vaccine brand other: Moderna; Vaccine brand: Pfizer/BioNTech; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 65-year-old male patient received bnt162b2, bnt162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 28Sep2022 as dose 5 (booster), single (Lot number: Gh9693), in left arm and on 15Jun2023 as dose 6 (booster), single (Lot number: 616796) at the age of 65 years, in left arm for covid-19 immunisation; bnt162b2 (BNT162B2), on 13May2022 as dose 4 (booster), single (Lot number: Fn2908), in left arm for covid-19 immunisation; bnt162b2 (BNT162B2), on 16Feb2021 as dose 1, single (Lot number: El3248), in left arm, on 09Mar2021 as dose 2, single (Lot number: En6199), in left arm and on 29Oct2021 as dose 3 (booster), single (Lot number: Fd0809), in left arm for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 02Oct2023 as dose 7 (booster), single (Lot number: 8057658), in left arm for covid-19 immunisation. The patient's relevant medical history included: "High blood pressure" (unspecified if ongoing); "known allergies: Sulfa" (unspecified if ongoing); "Cholesterol" (unspecified if ongoing); "gout" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Codeine, reaction(s): "Allergy". The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 02Oct2023, outcome "unknown", described as "Vaccine brand other: Moderna; Vaccine brand: Pfizer/BioNTech"; VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of vaccination failure, covid-19, interchange of vaccine products.